CStone Pharmaceuticals (PH4.F)
- Previous Close
0.1070 - Open
0.1070 - Bid 0.1020 x 182700
- Ask 0.1130 x 172600
- Day's Range
0.1070 - 0.1070 - 52 Week Range
0.0920 - 0.3660 - Volume
1,200 - Avg. Volume
1,296 - Market Cap (intraday)
136.684M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. Its products also comprise CS1002, CS2006, CS3005, CS2007, CS2008, CS6001, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Suzhou, China.
www.cstonepharma.comRecent News: PH4.F
Performance Overview: PH4.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PH4.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PH4.F
Valuation Measures
Market Cap
136.68M
Enterprise Value
51.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.26
Price/Book (mrq)
2.32
Enterprise Value/Revenue
0.11
Enterprise Value/EBITDA
-0.17
Financial Highlights
Profitability and Income Statement
Profit Margin
-155.97%
Return on Assets (ttm)
-26.79%
Return on Equity (ttm)
-96.55%
Revenue (ttm)
481.07M
Net Income Avi to Common (ttm)
-750.33M
Diluted EPS (ttm)
-0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.03B
Total Debt/Equity (mrq)
36.37%
Levered Free Cash Flow (ttm)
-469.85M
Company Insights: PH4.F
PH4.F does not have Company Insights